针对TNF/IAP途径与T细胞急性淋巴细胞白血病的抗CD3免疫疗法协同作用
Andrea Ávila Ávila1,2,3,4,5, Kanokporn Nuantang1,2,3,4,5, Mariana L Oliveira1,2,3,4,5
1Institut Curie, Orsay, France.
用抗CD3单克隆抗体 (mAbs) 向T细胞受体 (TCR) 显示出对T细胞急性淋巴细胞白血病 (T-ALL) 的承诺. 将抗CD3mAbs与TNF抑制剂或SMAC模拟剂结合起来,可以增强抗白血病效应,并改善T-ALL模型中的存活率.
科学领域:
- 血液瘤学 血液瘤学
- 免疫治疗是一种免疫疗法.
- 分子生物学分子生物学
背景情况:
- T细胞急性淋巴细胞白血病 (T-ALL) 是一种具有低于最佳治疗结果的侵袭性癌症.
- 反CD3单克隆抗体 (mAbs) 诱导T细胞受体 (TCR) 信号,促进白血病细胞死亡,但往往导致复发.
- 了解抗CD3治疗的耐药性机制对于开发更有效的治疗方法至关重要.
研究的目的:
- 确定能够增强抗CD3mAbs在T-ALL中的疗效的分子标.
- 研究TNFα/LTα信号传导在T-ALL对TCR向治疗的耐药性中的作用.
- 评估涉及抗CD3 mAbs与TNF抑制剂或SMAC模仿剂的组合策略.
主要方法:
- 用抗CD3mAbs.治疗的患者衍生T-ALL异种移植的转录组分析.
- 在体内研究中,使用乙坦塞普特 (TNFα/LTα抑制剂) 和比里纳潘特 (SMAC模仿剂) 与抗CD3 mAbs.结合使用.
- 在临床前T-ALL模型中评估白血病细胞扩张,细胞亡和宿主存活率.
主要成果:
- 抗CD3治疗提高了T-ALL中的TNFα,LTα和NF-κB信号元件的调节.
- 乙南塞普特通过克服TNF/TNFR生存途径,增强了抗CD3mAbs的抗白血病作用.
- 比里纳潘与抗CD3mAbs协同作用,抑制白血病扩散并改善生存率,依赖于RIPK1.
结论:
- 在T-ALL.中,TNF/TNFR生存途径代表了对TCR向免疫治疗的耐药性机制.
- 通过抑制TNFα/LTα或通过SMAC模拟剂准TNF介导的生存,可以克服抗CD3 mAbs的抗性.
- 涉及抗CD3mAbs与TNF抑制剂或SMAC模仿剂的组合疗法对T-ALL具有治疗潜力.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
12:16A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
